Skip to search formSkip to main contentSkip to account menu

AZD8330

Known as: ARRY-424704, ARRY-704, MEK Inhibitor AZD8330 
An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor AZD8330 specifically inhibits mitogen-activated… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Dihydropyridines
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
TRIM65 is a potential oncogenic protein via ERK1/2 on Jurkat and Raji cells: A therapeutic target in human lymphoma malignancies
In human lung cancer, Tripartite motif 65 (TRIM65) is documented as an important regulator in carcinogenesis. Knockdown of TRIM65… 
2017
2017
Chemical-biology approach to delineate the mechanism of action of HIV-1 latency reversing agents
Prostratin exhibits potent HIV-1 latency reversing activity, yet its molecular mechanism of action has not been defined in detail… 
2015
2015
ERK1/2抑制剂AZD8330对Burkitt淋巴瘤细胞株Raji细胞的作用及其机制研究
目的 探讨细胞外信号调节激酶1/2（ERK1/2）抑制剂AZD8330对Burkitt淋巴瘤细胞株Raji细胞的作用及其机制。 方法 Raji细胞用不同浓度的AZD8330进行处理；采用CCK-8检测细胞存活率；流式细胞术检测细胞凋亡情况；实时定量PCR… 
2009
2009
Abstract #3696: AZD8330 (ARRY-424704): Preclinical evaluation of a potent, selective MEK 1/2 inhibitor currently in phase I trials
The dual-specificity kinases MEK 1/2 play key roles in tumorgenesis by activating the serine/threonine kinases ERK 1/2. These… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)